HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
CartalaxHPLC ≥ 99%MS confirmed20mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Cartalax |
|---|---|
| Molecular formula | C12H19N3O8 |
| Molecular weight | 333.29 g/mol |
| Sequence | Ala-Glu-Asp |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 20mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | Store lyophilized powder sealed at -20°C, protected from light and moisture; short-term room-temperature transit is tolerated. After reconstitution, keep refrigerated at 2–8°C and use within the validated stability window. For laboratory research use only. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 3–7 days |
| Production lot | 500–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
About Cartalax.
Cartalax is a synthetic tripeptide (Ala-Glu-Asp) belonging to the Khavinson family of short peptide bioregulators, derived from cartilage- and connective-tissue-associated sequences. Available evidence is preclinical and cell-culture based, where it is investigated as a proposed tissue-specific gene-expression modulator acting on chondrocytes and fibroblasts; no applied-use dose is established.
Documentation
Batch documentation support for Cartalax lots.
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the Cartalax reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
Cartalax — frequently asked by B2B buyers.
What is Cartalax and in what format does Pepti supply it?
Cartalax is a synthetic Ala-Glu-Asp (AED) tripeptide bioregulator of the Khavinson short-peptide class. Pepti supplies it as a lyophilized white powder in sealed vials for laboratory research use, in a 20 mg vial format with a 50-vial minimum order, and offers private-label / OEM options.
What documentation ships with each batch?
Each batch is accompanied by a Certificate of Analysis (COA) reporting HPLC purity and mass-spectrometry (MS) identity confirmation. Additional documentation such as TDS and safety data can be provided to qualified B2B accounts on request.
What purity does Pepti provide?
Cartalax is manufactured to a typical purity of ≥99% by HPLC. The exact figure for each lot is stated on the batch-specific COA, and tighter specifications can be quoted on RFQ.
Do you offer private-label / OEM and custom quantities?
Yes. Pepti is a China-based OEM and private-label manufacturer. Custom fill weights, vial labeling, kitting, and bulk volumes beyond the catalog 20 mg / 50-vial MOQ are available under RFQ.
Is a CAS number available for Cartalax?
The exact all-L Ala-Glu-Asp tripeptide is catalogued in PubChem (CID 87815447) but has no assigned CAS registry number, and some CAS values circulating online actually map to unrelated compounds. Batch identity is confirmed by mass spec, and any regulatory identifiers are confirmed on RFQ.
Related compounds